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arily conserved on microorganisms. This contrasts to
the adaptive immune system where the recognition mol-
ecules (antibodies and T cell antigen receptors) achieve
their diversity through ontogenic rearrangement of the
genes.
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One plasma protein, which enables the innate immuneUniversity of Aarhus
system to distinguish self from non-self, is mannan-DK 8000, Aarhus
binding lectin (MBL), a member of the complement sys-Denmark
tem. The complement system comprises a series of2 Department of Biochemistry
plasma and cell membrane proteins (Law and Reid,Fukushima Medical University
1995). It represents a well-known antimicrobial defenseFukushima 960-1295
mechanism of major clinical importance (Walport, 2001a,Japan
2001b) but also serves as a natural adjuvant, enhancing3 MRC Immunochemistry Unit
and directing the adaptive immune response (Carroll,University of Oxford
2000). Thus, animals deficient in complement factor C3OX1 3QU, Oxford
or C4, either acquired (Pepys, 1974) or genetically as aUnited Kingdom
result of disruption of the genes by homologous recom-
bination, have an impaired humoral response to T cell-
dependent antigens associated with reduced numberSummary
and size of germinal centers and impaired retention of
antigen on folicular dendritic cells (Fischer et al., 1996).The mannan-binding lectin (MBL) pathway of comple-
This results from defaults in the interaction between thement activation is part of the innate immune defense.
fragments of complement factor C3 (C3b and/or C3d)The binding of MBL to microbial carbohydrates acti-
and C4 (C4b) attached to the antigen and receptors forvates the MBL-associated serine proteases (MASPs),
these fragments (Fearon and Carroll, 2000).which recruit the complement factors, C4 and C2, to
The initiation of the complement cascade in the earlygenerate the C3 convertase or directly activate C3.
phase of an immune response may be achieved throughWe present a phylogenetically highly conserved mem-
three pathways. (1) Natural polyreactive IgM antibodies,ber of the MBL complex, MASP-3, which is generated
secreted by B-1 cells, can lead to activation of comple-through alternative splicing of the MASP-1/3 gene. The
ment via the classical pathway. (2) The deposition ofdesignation of MASP-3 as a protease is based on ho-
fragments of C3 on certain structures that impede themology to known MASPs. Different MBL oligomers
control of the alternative pathway will initiate this path-were found to have distinct MASP composition and
way. (3) The third pathway of complement activation,biological activities. MASP-1, MAp19, and direct C3-
the mannan-binding lectin (MBL) pathway, also termedcleaving activity are associated with smaller oligomers
the lectin pathway, was recently discovered. This path-whereas MASP-3 is found together with MASP-2 on
way is initiated on surfaces with a carbohydrate decora-larger oligomers. MASP-3 downregulate the C4 and
tion not normally found in the body.
C2 cleaving activity of MASP-2.
Deficiency of MBL is emerging as the most common
human immune defect (Turner and Hamvas, 2000). The
Introduction level of MBL is largely genetically determined with muta-
tions in the coding region as well as in the promoter
The host defense against microorganisms relies on both region, causing low concentrations (Lipscombe et al.,
innate and adaptive elements (Hoffmann et al., 1999; 1996; Madsen et al., 1995). MBL has the ability to bind
Medzhitov and Janeway, 2000). Innate immunity offers to carbohydrate structures on the surface of microor-
the main resistance to a microbial pathogen within the ganisms (including bacteria, viruses, and fungi) and me-
first minutes, hours, or days of an infection. However, diate the deposition of complement factors (Ikeda et al.,
it has lately transpired that the innate immune system 1987; Matsushita and Fujita, 1992; Ji et al., 1993; Thiel
also plays a significant role for ensuring the adaptive et al., 1997). This promotes killing of the microorganism
immune response (Dempsey et al., 1996; Fearon and via the membrane attack complex, as well as through
Locksley, 1996). The innate immune system is activated enhanced phagocytosis of the microorganism due to
as soon as pathogens or enviromental antigens are the opsonizing effect of deposited C3b. MBL may also
flagged by soluble or membrane-bound recognition act as an opsonin itself (Kuhlman et al., 1989) through
molecules. These are germline encoded proteins and interaction with phagocytic receptors (Ghiran et al.,
have as such evolved through natural selection to effi- 2000). Interestingly, a recent report suggests involve-
ciently detect patterns (pathogen-associated molecular ment of MBL in the class switch of antibody production
patterns [PAMPs] [Janeway, 1989]) that are evolution- toward MBL-reactive carbohydrate epitopes (Selander
et al., 1999).
The biological significance of MBL was realized when4 Correspondence: st@microbiology.au.dk
MBL deficiency was found to be the likely cause of5 Present address: Department of Microbiology and Immunology,
University of Leicester, Leicester, United Kingdom. opsonin deficiency in children with an unexplained pro-
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pensity for frequent, often serious infections (Super et
al., 1989), an observation subsequently supported by
numerous epidemiological investigations (Summerfield
et al., 1997; Garred et al., 1999).
MBL belongs to the collectin family of proteins and
is an oligomer of structural subunits each composed
of three identical 30 k Mr polypeptides with a C-type
carbohydrate recognition domain joined to a collage-
nous region (Turner, 1996). The overall structure is thus
similar to that of C1q, the antibody-recognizing moiety
of the first component of the classical complement acti-
vation pathway.
The activation via MBL was found to proceed via spe-
cific MBL-associated serine proteases (MASPs) of a
modular structure identical to that of C1r and C1s, i.e.,
an A chain composed of CUB1, EGF, CUB2, CCP1, and
CCP2, joined by a linker to the B chain encompassing
the serine protease domain (Matsushita and Fujita, 1992;
Thiel et al., 1997). The MBL complex has been reported
to contain MASP-1, MASP-2, and a smaller nonenzy-
matic component, MAp19 (Stover et al., 1999) or sMAP
(Takahashi et al., 1999). The stoichiometry of the MBL/ Figure 1. Characterization of MASP-3 and Its Association with MBL
MASP complex is unknown, and it appears that the (A) Two-dimensional SDS-PAGE Western blot of MBL complexes
MASPs do not function in concert as do C1r and C1s; purified by affinity chromatography on mannan-Sepharose. The first
rather MASP-1 shows the ability to activate C3 (Matsu- dimension (horizontal) was run under nonreducing conditions. The
lane was then reduced and run in the second dimension. The gelshita and Fujita, 1992, 1995a; Matsushita et al., 2000)
was blotted and developed with antibody against the N-terminal ofwhile MASP-2 activates C4 and C2 (Thiel et al., 1997;
the 42 k Mr protein. The second dimension gel was prepared withMatsushita et al., 2000; Vorup-Jensen et al., 2000). We
a separate well for a reduced sample of MBL complexes (lane R),
report here on the discovery of a third MASP. We de- which thus illustrates the pattern after standard one-dimensional
scribe its association with distinct MBL complexes and electrophoresis. The positions of the Mr markers are indicated.
discuss evolutionary aspects of MASP-3. (B) Association of MASP-3 with MBL. Samples (100l) of sera diluted
with an equal volume of TBS were incubated in microtiter wells
coated with monoclonal anti-MBL antibody, eluted with 100 l SDSResults
sample buffer for 10 identical wells (Thiel et al., 2000), and examined
by SDS-PAGE Western blotting using antibody against the N-termi-
Identification of a MASP nal of the 42 k Mr protein. The samples were: 1, normal serum
Analysis by SDS-PAGE of plasma proteins, purified containing MBL 2 g/ml; 2, purified MBL (Vorup-Jensen et al., 2000)
(1 g); 4 and 6, two MBL-deficient sera (MBL concentrations  20through calcium-dependent binding to matrices deriva-
ng/ml); 3 and 5, the same two MBL-deficient sera with MBL addedtized with GlcNAc, revealed an unidentified protein of
to 2 g/ml.42 k Mr. The N-terminal sequence of the protein sug-
gested that it represented the start of a serine protease
domain. This sequence, as well as those of some tryp-
not when MBL-deficient serum was applied. When MBLsin-generated peptides, is shown underlined in the sub-
was added to MBL-deficient serum, the protein wassequently determined complete sequence of the protein
again bound to the solid phase (Figure 1B, lanes 3 and(see below).
5). The protein was accordingly termed MBL-associatedAntibody was raised against a synthetic 19 amino acid
serine protease-3 (MASP-3).residue peptide representing the N-terminal sequence.
Two-dimensional SDS-PAGE and Western blotting of a
lectin preparation using this antibody as a probe re- Association of MASP-3 with Distinct Subsets
vealed that the presumed serine protease domain of 42 of MBL Complexes
k Mr was derived from a protein of Mr 105 k Mr. Before MBL complexes could be separated into different struc-
activation, the 105 k Mr protein forms a disulphide-linked tural and functional forms by ion-exchange chromatog-
dimer (Figure 1A). Activation splits the 105 k Mr protein raphy as well as by sucrose gradient centrifugation. Four
into 42 k Mr and 58 k Mr chains. The longer chain is not distinct MBL bands, MBL-I, II, III, and IV, were revealed
seen in these Western blots, as the antibody used does by nonreducing SDS-PAGE, with mobilities correspond-
not detect it. The structure thus resembles the A and B ing to approximate Mrs of 275 k Mr, 345 k Mr, 580 k Mr,and
chain structure of other serine proteases with the shorter 900 k Mr (Figure 2B). On ion-exchange chromatography,
B chain encompassing the serine protease domain. they were eluted in that order by increasing salt concen-
tration, and on sucrose gradient centrifugation they
showed increasing sedimentation rates in the same or-Association of the Serine Protease with MBL
Analytical affinity procedures showed that the protein der (Figures 2A, 2B, and 2G). Following both fraction-
ation procedures, MASP-1 and MAp19 were found to beoccurred in plasma complexed with MBL (Figure 1B).
The protein was thus bound to solid-phase anti-MBL associated largely with MBL-I, and MASP-2 and MASP-3
largely with MBL-II. The ability to activate C4, the firstantibody when MBL-sufficient serum was applied, but
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Figure 2. MBL Complexes of Different Sizes
and Compositions
(A) Sucrose gradient centrifugation showing
the C4 activating capacity and the MBL con-
tent of the fractions. The positions of 7 S IgG
and 19 S IgM are indicated. (B) SDS-PAGE
Western blot of the fractions developed with
anti-MBL antibody, (C) with anti-MASP-1 an-
tibody, (D) with anti-MASP-2 antibody, (E)
with anti-MASP-3 antibody, (F) with anti-
MASP-2 antibody reacting with MAp19, (G)
MBL in fractions from ion-exchange chroma-
tography, and (H) C3 activating capacities of
the same fractions (note the C3a chain in
lanes 4 and 5).
step in generating the C3 convertase, C4bC2b, coincided ure 3A). The activity of rMBL-rMASP-2 complexes
(Vorup-Jensen et al., 2000) was similarly inhibited bywith the MBL-II complexes (Figure 2A). Also, when frac-
tions from the ion-exchange chromatography were tested rMASP-3 (data not shown). The controlling activity of
MASP-3 appears to be mediated through competitivethe C4 activation could be assigned to the MASP-2
containing fractions (data not shown). The direct activa- inhibition of association of MASP-2 to MBL (compare
lane 1 with 3 and 4 with 6, Figure 3B). At the same time,tion of C3 was associated with the MBL-I complexes
(Figure 2H). a decrease could be seen in the activation of the MASP-2
still associated with MBL (observe the 52 k Mr bandMBL complexes were removed from serum through
binding to solid phase anti-MBL. Western blotting analy- representing the A chain of activated MASP-2, lanes 7
and 9, Figure 3B). The band at 75 k Mr represents thesis showed that all the MBL but only part of the MASP-3
was recovered from the solid phase. The residual MASP-3 proenzyme form of MASP-2. There was no indication of
enzymatic cleavage of MASP-2 by MASP-3.in the supernatant could be recovered by adding further
MBL and repeating the affinity step (data not shown).
The Primary Structure of MASP-3
and the Organization of the GeneActivity of MASP-3
We examined the functional activity of MASP-3 by incu- Further sequencing of MASP-3-derived peptides
yielded amino acid sequences, which were used to de-bating rMASP-3 with MBL complexes. This revealed a
pronounced inhibitory activity of rMASP-3 on the activa- sign and synthesize degenerated oligonucleotides. These
were used for PCR amplification, yielding a 174 basetion of C4 by MBL complexes purified from plasma (Fig-
Immunity
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the 10 exons encoding the MASP-1 A chain and the
6 exons encoding the MASP-1 B chain. The relevant
fragments were sorted on the basis of the published
genome sequence of MASP-1 (Endo et al., 1998), yield-
ing the genomic structure shown schematically in Figure
4C. The exon for the MASP-3 B chain is located between
the 10 exons encoding the MASP-1 A chain and the 6
exons encoding the MASP-1 B chain.
Primers were synthesized corresponding to the 5 and
3 ends of the MASP-3 B chain and used for PCR amplifi-
cations from genomic DNA and liver cDNA. Both reac-
tions yielded DNA fragments, which were cloned and
sequenced and found to agree 100% with the sequence
for the B chain in the database. Thus, in contrast to the
MASP-1 B chain but like the B chains of MASP-2, C1r,
and C1s, the MASP-3 B chain is encoded by a single
exon.
Cloning of MASP-3 cDNA from a human liver library
revealed a transcription product composed of a com-
mon MASP-1/3 A chain and a unique MASP-3 B
chain. The largest clone, encoding full-length MASP-3
(pMASP-3;4.1) comprises 3595 bp, starting with a 5
untranslated region of 90 bp, followed by an open read-
ing frame (ORF) of 2184 bp and a 3 untranslated region
of 1321 bp, and ending with a poly-A tail. The nucleotide
sequence of pMASP-3;4.1 has been deposited in Gen-
Bank (accession number AF284421). The amino acid
sequences of the sequenced peptides were identified
in the sequence deduced from the clone (Figure 4A).
The ORF encodes a polypeptide chain of 728 amino
acids, including a signal peptide of 19 residues. Three
N-glycosylation sites are found in the B chain and four
Figure 3. MASP-3 Inhibits the MBL Pathway in the A chain. Omitting the signal peptide, the calculated
mass is 81,873 as compared with Mr105 k Mr observed(A) Dilutions of rMASP-3 (filled circles) or control (open circles) were
incubated with plasma-derived MBL complexes in mannan-coated on SDS-PAGE. The calculated isoelectric point is 5.02,
wells, C4 was added, incubated at 37C, and bound C4 fragments and the molar extinction coefficient at 280 nm is 121,610
were quantified with Eu-labeled anti-C4 antibody. Activity (%) was (absorbance of 1 g/liter  1.49). The alternative splicing
read from a standard curve based on dilutions of MBL complexes.
site was shown to be situated immediately after exonrMASP-3 was in this experiment used in the form of culture superna-
10. The open reading frame of the B chain starts withtants of transfected cells with supernatant of sham-transfected cells
a 42 bp untranslated sequence followed by the codonsas control. The same results were obtained with rMASP-3 purified
by ion-exchange chromatography. for the 14 residue link region. This link region precedes
(B) Western blotting analysis of the inhibitory activity of MASP-3 on the activation site where the split between the A and B
MASP-2. MBL (100 ng/ml) (MASP free plasma derived MBL) (Vorup- chains takes place (Figure 4C).
Jensen et al., 2000) and rMASP-2 (10 ng/ml) were mixed and incu-
The last domain of the A chain, CCP2, is encoded bybated for 2 hr at 37C without rMASP-3 or with 100 or 500 ng/ml
exons 9 and 10. Exon 10 is followed by an intron andrMASP-3 in mannan-coated wells. Supernatant was collected. The
the exon encoding the MASP-3 B chain. This structurewells were washed and bound material eluted with sample buffer.
Supernatant and eluate were subjected to SDS-PAGE at reducing was confirmed by PCR on human liver cDNA using a primer
or nonreducing conditions, and blotted and developed with anti- pair corresponding to a sequence from exon 9 of the
MASP-2 antibody. The amount of MASP-2 in the supernatant in- MASP-1 A chain and a sequence from the MASP-3 B
creases with MASP-3 addition. In parallel the amount of MBL bound
chain. Antibody raised against a peptide representingMASP-2 decreases. The activation of the bound MASP-2 decreased
the 20 N-terminal residues of the MASP-1 A chain recog-upon MASP-3 addition as seen in the samples run at reducing condi-
nized MASP-3 on Western blots as identified in paralleltions (the 52 k Mr band represents the A chain of activated MASP-2).
by the anti-MASP-3 B chain antibody and by an antibody
raised against a peptide representing the MASP-3 link
region (data not shown), thus identifying the MASP-3nucleotide fragment from liver cDNA. The deduced
protein as a product arising from alternative splicing.amino acid sequence (Figure 4A) classified the protein
as a protease homologous to the B chains of MASP-1,
MASP-2, C1r, and C1s. The 174 bp DNA was found to Evolutionary Aspects
Database searches revealed homology of the MASP-3be included in the genomic sequence AC007920. This
230 kb sequence of unsorted fragments was found to B chain with sequences logged for shark and carp MASP
(Endo et al., 1998; Figure 4B). The sequence identitiescontain the entire MASP-3 B chain sequence as judged
by comparison with the B chains of MASP-1, MASP-2, are 65% and 62%, respectively, whereas those between
human MASP-3 B chain and human MASP-1 andC1r, and C1s. In addition, it contained the sequence for
MASP-3 and the MBL Complement Activation Pathway
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MASP-2 B chains are only 37% and 38%, respectively. within a species (Figure 5). The coding region of the
MASP-1/3 gene comprises from the 5 end: 10 exonsLamprey MASP shares a number of structural features
encoding the common MASP-1/3 A chain, followed bywith shark and carp MASP (Endo et al., 1998).
a single exon encoding the MASP-3 link region andTwo sequences logged for porcine DNA together match
protease domain, and next the 6 exons encoding thethe 182 C-terminal residues of the human MASP-3 B
MASP-1 link region and protease domain. There arechain. A 95% amino acid sequence identity between the
poly-A regions following the exons encoding the pro-two proteins was revealed, with only three differences
tease domains of both MASP-3 and MASP-1. Thewithin the first 170 residues (Figure 4B). The nucleotide
MASP-3 B chain presumably arose through partial geneidentity was 89%.
duplication of the MASP-1 gene. After modifications in-
cluding loss of the introns and loss of the cysteinesDiscussion
forming the histidine loop, the locus encompassing the
MASP-1/3 A chain and the MASP-3 B chain proceededWe have identified and characterized a MBL-associated
to duplicate and diversify to generate the group of AGYserine protease, MASP-3. Thus, the family of MASP-
MASP-like serine proteases.like serine proteases now encompasses five members:
Another aspect of this study is the demonstration ofMASP-1, MASP-2, MASP-3, C1r, and C1s. All these pro-
the selective association of MASP-3 with MBLs of ateins show identical domain organization, even though
restricted degree of oligomerization (Figure 2). Likewise,the overall amino acid sequence identity is only 40%.
the other MASPs and MAp19 show a restricted distribu-The family name is suggested since MASP-1 phyloge-
tion among MBL oligomers. The restricted distributionnetically stands out as the likely earliest of these proteins
of the MASPs was found to be reflected in the biologicaldue to the chymotrypsin-like nature of its serine prote-
activities of the complexes, with the smaller oligomersase domain. As is the case for chymotrypsin, the prote-
containing MASP-1 and MAp19 showing direct activa-ase domain of MASP-1 is encoded by several exons,
tion of C3. Higher oligomers containing MASP-2 acti-and the structure around the active site histidine is stabi-
vated C4 and C2 to generate the C3 convertase C4bC2b.lized by a disulphide bridge (the histidine loop). The
This agrees with previous observations on the activityactive site serine residue in MASP-1, like in chymotryp-
of isolated MASP-1 (Matsushita and Fujita, 1995a) andsin, is encoded by a TCN codon (N  any nucleotide).
MASP-2 (Thiel et al., 1997; Matsushita et al., 2000). ItThese features are also found for MASPs in protochor-
has also recently been shown that complexes com-dates (MASPa and MASPb of the ascidian Halocynthia
posed only of rMASP-2 and MBL can activate C4 (Vorup-roretzi; Endo et al., 1998), and also in the other serine
Jensen et al., 2000). MASP-3 was largely found withproteases of the complement system, factor D, factor
the MASP-2 containing complexes. Superior separationB, C2, and factor I. In contrast, for MASP-2, MASP-3,
procedures are needed to clearly resolve the differentC1r, and C1s the serine protease domain is encoded by
complexes for determining their function and composi-a single exon, there is no histidine loop, and the active
tion, and to establish the degree of oligomerization ofsite serine is encoded by AGY (Y  C or T). This is the
the MBL. It is noteworthy that the size separations at
case for mammals as well as for MASPs in the frog,
physiological conditions were directly reflected in the
carp, shark, and lamprey. The split exon structure of the
mobilities of the MBL oligomers on nonreduced SDS-
gene and the codon usage are features that have no
PAGE, suggesting that the oligomerization is defined by
structural implications, but they serve as useful markers disulphide bridges and not by noncovalent interactions.
for phylogenetic considerations. The histidine loop The presence of distinct MBL oligomers agrees with
could have functional implications. A phylogenetic tree previous findings (Lu et al., 1990; Lipscombe et al., 1995;
suggests that the AGY type diverged from the TCN type Yokota et al., 1995). It was unexpected to find that the
before the emergence of primitive vertebrates (Endo et MASPs are differentially associated with distinct MBL
al., 1998). While C1r and C1s have been found only in oligomers.
advanced vertebrates, the early appearance of MASPs After storage at 4C of the different forms of MBL
suggests the premordial nature of MASPs and the MBL complexes separated by chromatography, we do not
pathway of complement activation. The maintenance of see any change in the oligomerization as analyzed by
these proteins in all higher animals points to importance SDS-PAGE, suggesting that the oligomers once formed
of this system for the preservation of an optimal innate are stable. It is remarkable that the protein generating
immune defense. machinery is capable of producing these distinct forms
MASP-3 is unusually conserved with pig and rat (W. from a single polypeptide chain.
Schwable, personal communication) B chains both The current study of oligomers was directed at the
showing more than 90% sequence identity to the human wild-type form of MBL (the A/A allotype) only. In MBL
B chain, and an identity of 62% and 65% to carp and from pooled plasmas one will observe also a very minor
shark MASP-3, respectively. Strikingly, in a consecutive staining on the Western blots of molecular forms at
sequence of 170 residues there are only three differ- around 100 k Mr, representing MBL from individuals with
ences between human and pig MASP-3 B chain. In com- mutations in the MBL gene (Lipscombe et al., 1995).
parison, the B chains of the other four MASP-like serine These mutated forms previously have been found not
proteases show a more usual degree of conservation to bind MASP-1 and not to activate complement (Mat-
of about 80% between mammals (e.g., human and rat) sushita et al., 1995b).
and 30% to 40% between mammalian and lower verte- To understand the biology of the MASPs, it is impor-
brate homologs. This is the same degree of conservation tant to realize that only a proportion of these proteases
are associated with MBL in serum, as has been demon-seen between the different MASP-like serine proteases
Immunity
132
MASP-3 and the MBL Complement Activation Pathway
133
Figure 5. Identities between B Chains of the MASP-like Serine Proteases
Percentage identity was calculated based on the alignment of the amino acid sequences. The sequences used for the alignments have the
following accession numbers: laMASP, AB009075; xeMASP-1, D83276; xeMASP-2, AB009072; huC1r, M14058; huC1s, CAA29817; asMASPa,
BAA19762; asMASPb, BAA19763; moMASP-1, NP 032581; and moMASP-2, BAA34674. The following abbreviations were used: hu, human;
mo, mouse; xe, Xenopus; la, lamprey; sh, shark; as, ascidian; and ca, carp.
strated for MASP-1 and MASP-2 (Terai et al., 1997; Thiel Clos, 2000) and natural antibodies (Ochsenbein and
Zinkernagel, 2000), are involved. Upon binding to theiret al., 2000). By depleting serum of MBL complexes and
analyzing for residual MASP-3 by Western blotting, we ligands, these molecules mediate signals to other com-
ponents of the body’s defense system, establishing afound the same to be true for this protein.
The functional activity of MASP-3 was assessed in range of immediate antimicrobial defense functions but
also influencing the selection and the modes of the fol-experiments on opsonization, i.e., MBL/MASP-2 medi-
ated C4b deposition on mannan-coated surfaces. In such lowing adaptive immune responses (Medzhitov and
Janeway, 1997). The new protein MASP-3, characterizedassays, MASP-3 demonstrated inhibition of MASP-2 ef-
fected by a combination of competitive inhibition of in the present paper, as well as the other MASPs have
the potential to perform such signaling functions whenMASP-2 association with MBL and inhibition of activa-
tion of the MBL-associated MASP-2. The initiating com- MBL binds to carbohydrate structures.
plex of the classical complement activation pathway,
Experimental ProceduresC1, is a single entity comprised of the hexameric C1q
in complex with two C1r and two C1s molecules. It
Amino Acid Sequencingwas initially expected that the MBL complex could be
A lectin preparation purified from plasma (Thiel et al., 1997) was
modeled on the C1 structure, but the present report subjected to SDS-PAGE, transferred to a PVDF membrane, and
emphasizes structural and functional differences be- stained with Coomassie brilliant blue. The 42 k Mr band was cut
out and subjected to sequencing on an applied biosystems proteintween the two complexes.
sequencer. Peptides were prepared by tryptic digestion of the 42Limitation of infection upon exposure to microbes is
k Mr band from a Coomassie-Blue-stained SDS-PAGE gel, fraction-of utmost importance for the survival of the individual.
ated by reverse phase chromatography, and the peptides in theThus, several systems have evolved for this purpose.
major peaks were sequenced.
Cellular components, e.g., toll-like receptors (Medzhitov
and Janeway, 2000) and receptors for “non-self” carbo- Purification and Physical Characterization of MBL Complexes
hydrate compositions (Hoffmann et al., 1999), as well MBL complexes were purified from normal human plasma by affinity
chromatography on mannan-Sepharose in the presence of enzymeas humoral factors, e.g., MBL, C-reactive protein (Du
Figure 4. The Sequence and the Genomic Organization of MASP-3
(A) Deduced amino acid sequence of the MASP-3 B chain. The sequence is aligned with those of human MASP-1 (NM001879) and human
MASP-2 (Y09926) B chains.
(B) Alignment of human MASP-3 with shark (AB009074) and carp (AB009073) MASP-3 B chains and a partial pig MASP-3 sequence (a
combination of AW414970 and BE030550). (*) identical residues, (:) conserved substitutions, (.) semiconserved substitutions. The alignments
were made with BLOSUM 62. Aligned cysteines are boxed. The cysteines in the histidine loop of MASP-1 are shaded. The three potential N-gly-
cosylation sites of MASP-3 are in bold. The three arrows indicate the active site residues of the serine proteases. Sequences identified by
protein sequencing are underlined.
(C) Genomic organization of the exons (drawn to scale) encoding MASP-1 and MASP-3 and comparison of the derived proteins.
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